Association between beta-blockers, other antihypertensive drugs and psoriasis: Population-based case-control study

British Journal of Dermatology

Volumn 158, Issue 6, 2008, Pages 1299-1307

  Brauchli, Y B ^a   Jick, S S ^b   Curtin, F ^c   Meier, C R ^a,b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c MERCK SERONO S A   (Switzerland)

Author keywords

Antihypertensive drugs; Beta blockers; Cardiovascular risk factors; Psoriasis

Indexed keywords

ACEBUTOLOL; ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; CALCIPOTRIOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CARTEOLOL; CARVEDILOL; CELIPROLOL; CLONIDINE; COAL TAR; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DITHRANOL; DIURETIC AGENT; ESMOLOL; ETRETIN; LABETALOL; METOPROLOL; NADOLOL; NEBIVOLOL; OXPRENOLOL; TAZAROTENE; TIMOLOL; UNINDEXED DRUG; VERAPAMIL;

ADOLESCENT; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHILD; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; DRUG ERUPTION; DRUG USE; FEMALE; HUMAN; INCIDENTAL FINDING; INFANT; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; RISK ASSESSMENT; UNITED KINGDOM;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGE DISTRIBUTION; AGED; ANTIHYPERTENSIVE AGENTS; CASE-CONTROL STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RISK ASSESSMENT; SEX DISTRIBUTION;

EID: 43749119138     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08563.x     Document Type: Article

References (34)

1. Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004 3 : 121 8.
2. Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001 15 : 16 17.
3. Gelfand JM, Weinstein R, Porter SB et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 2005 141 : 1537 41.
4. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004 135 : 1 8.
5. Tagami H. Triggering factors. Clin Dermatol 1997 15 : 677 85.
6. Tsankov N, Kazandjieva J, Drenovska K. Drugs in exacerbation and provocation of psoriasis. Clin Dermatol 1998 16 : 333 51.
7. Abel EA, DiCicco LM, Orenberg EK et al. Drugs in exacerbation of psoriasis. J Am Acad Dermatol 1986 15 : 1007 22.
8. Naldi L, Chatenoud L, Linder D et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005 125 : 61 7.
9. Naldi L, Parazzini F, Peli L et al. Dietary factors and the risk of psoriasis. Results of an Italian case-control study. Br J Dermatol 1996 134 : 101 6.
10. Neimann AL, Shin DB, Wang X et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006 55 : 829 35.
11. Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986 172 : 298 304.
12. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995 32 : 982 6.
13. Cochran RE, Thomson J, Fleming K, McQueen A. The psoriasiform eruption induced by practolol. J Cutan Pathol 1975 2 : 314 19.
14. Felix RH, Ive FA, Dahl MG. Cutaneous and ocular reactions to practolol. Br Med J 1974 4 : 321 4.
15. Kauppinen K, Niemi KM, Salo OP. Cutaneous reactions to practolol. Clinical and histopathological study. Ann Clin Res 1976 8 : 232 40.
16. O'Brien M, Koo J. The mechanism of lithium and beta-blocking agents in inducing and exacerbating psoriasis. J Drugs Dermatol 2006 5 : 426 32.
17. Marquart-Elbaz C, Grosshans E, Lipsker D, Lipsker D. Sartans, angiotensin II receptor antagonists, can induce psoriasis. Br J Dermatol 2002 147 : 617 18.
18. Cohen AD, Kagen M, Friger M, Halevy S. Calcium channel blockers intake and psoriasis: a case-control study. Acta Derm Venereol (Stockh) 2001 81 : 347 9.
19. Wilkin J. Exacerbation of psoriasis during clonidine therapy. Arch Dermatol 1981 117 : 4.
20. Cohen AD, Bonneh DY, Reuveni H et al. Drug exposure and psoriasis vulgaris: case-control and case-crossover studies. Acta Derm Venereol (Stockh) 2005 85 : 299 303.
21. Garcia Rodriguez LA, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998 45 : 419 25.
22. Jick H. A database worth saving. Lancet 1997 350 : 1045 6.
23. Jick SS, Kaye JA, Vasilakis-Scaramozza C et al. Validity of the General Practice Research Database. Pharmacotherapy 2003 23 : 686 9.
24. Gelfand JM, Berlin J, van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003 139 : 1425 9.
25. Gelfand JM, Neimann AL, Shin DB et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006 296 : 1735 41.
26. Gelfand JM, Shin DB, Neimann AL et al. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006 126 : 2194 201.
27. Gelfand JM, Wang X, Qing L et al. Epidemiology and treatment patterns of psoriasis in the General Practice Research Database (GPRD). Pharmacoepidemiol Drug Saf 2005 14 (Suppl. S23.
28. Dika E, Varotti C, Bardazzi F, Maibach HI. Drug-induced psoriasis: an evidence-based overview and the introduction of psoriatic drug eruption probability score. Cutan Ocul Toxicol 2006 25 : 1 11.
29. Heng MC, Heng MK. Beta-adrenoceptor antagonist-induced psoriasiform eruption. Clinical and pathogenetic aspects. Int J Dermatol 1988 27 : 619 27.
30. Sondergaard J, Wadskov S, Jensen HA, Mikkelsen HI. Aggravation of psoriasis and occurrence of psoriasiform cutaneous eruptions induced by practolol (Eraldin). Acta Derm Venereol (Stockh) 1976 56 : 239 43.
31. Chang YC, Wu WM, Chen CH et al. Association between the insertion/deletion polymorphism of the angiotensin I-converting enzyme gene and risk for psoriasis in a Chinese population in Taiwan. Br J Dermatol 2007 156 : 642 5.
32. Cuschieri J, Gourlay D, Garcia I et al. Slow channel calcium inhibition blocks proinflammatory gene signaling and reduces macrophage responsiveness. J Trauma 2002 52 : 434 42.
33. Fansa I, Gol M, Nisanoglu V et al. Does diltiazem inhibit the inflammatory response in cardiopulmonary bypass? Med Sci Monit 2003 9 : PI30 6.
34. Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006 54 : 614 21.